Apple disclosures on Jobs 'subject of SEC review'

SAN FRANCISCO: Apple Inc's disclosures about Steve Jobs' health remain under scrutiny by US Securities and Exchange Commission investigators over how his condition went from "relatively simple" to "more complex" in nine days, said a person familiar with the matter.

A pivotal question for regulators is what Apple's board knew at the time of Jobs' Jan 5 announcement that he had a hormone imbalance and a Jan 14 statement that he was taking a five-and-a-half month medical leave, said the person, who declined to be identified because the probe is confidential.

Jobs went on to have a liver transplant during his leave. SEC investigators want to be sure that Jobs' January disclosures didn't mislead investors, the person said. Bloomberg News reported in January that the SEC had opened the probe.